Interaction Studies between Sitagliptin Phosphate and Atorvastatin Calcium in Streptozotocin Induced Chronic Type II Diabetes Mellitus Rat Model
Diabetes Mellitus describes a metabolic disorder which is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion. Various combination therapies are used to treat metabolic syndrome and includes an antidiabetic drug to control the blood glucose levels, anti-hyperlipidemic drug to control cholesterol and lipid levels. In this study interaction between Sitagliptin phosphate, drug from antidiabetic class i.e. dipeptidyl peptidase IV inhibitor and Atorvastatin calcium other from antihyperlipidemic class i.e. HMG-COA reductase inhibitor was evaluated in Streptozotocin and High-fat diet induced type II diabetic rat model. The combination was selected since Sitagliptin phosphate and Atorvastatin Calcium share a common metabolizing enzyme, CYP3A4, there might be chances of interaction taking place due to the co-administration of the same. Bioanalytical method was developed and validated according to ICH guidelines for evaluation of pharmacokinetic parameters. Pharmacodynamic parameters such as Serum glucose, Serum cholesterol, Serum triglyceride levels and other related tests were performed to evaluate interaction at pharmacodynamic level. Results suggest that, at pharmacodynamic and pharmacokinetic level, this combination treatment can have good application in managing blood glucose level and lipid level as well. Being not affected by the CYP450 metabolisms as when correlated with plasma levels at their particular half-life, we suggest that Sitagliptin phosphate and atorvastatin calcium on simultaneous administration will not lead to cause any toxic effect..
2. Bernini F, Poli A, Paoletti R; Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Journal of Cardiovascular Drugs Therapeutics; 2001; 15; 211-218.
3. Chu XY, Bleasby K, Yabut J.; Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics; 2007; 321; 673-683.
4. Dongyang L, Jiang J, Zhou H, Hu P.; Quantitative Determination of Atorvastatin and Para-hydroxy Atorvastatin in Human Plasma by LC–MS–MS. Journal of Chromatographic Science.; 2008; 46; 862-866.
5. Dubala A, Khatwal R, Kosaraju J, Meda V, Malay S.; Bio-analytical method development and validation of sitagliptin phosphate by RP-HPLC and its application to pharmacokinetic study. International Journal of Pharmacy and Pharmaceutical Sciences; 2012; 4; 691-694.
6. Entidhar J, Akkam A, Rasool A, Adnan A, Badwan D, Nawzat D.; Development and validation of a sensitive and accurate method for Determination of Atorvastatin and Rosuvastatin in rat plasma by RP-HPLC with UV detection method. International Journal of Pharmacy and Pharmaceutical Sciences; 2013; 5; 211-219.
7. European union agency; Bio-analytical method validation by guidelines of EMASM, available at; 2011: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin...
8. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H.; Role of oxidative stress in atherosclerosis. American Journal of Cardiology; 2003; 91; 3A; 7A–11A.
9. Inamdar H, Mhaske A.; RP-HPLC Method for Simultaneous Determination of Metformin Hydrochloride, Rosiglitazone and Sitagliptin – Application to Commercially Available Drug Products. International Journal of Pharmaceutical Sciences and Research; 2012; 3; 3267-3276.
10. Kumar P, Narsimha R, Reddy N.; Simultaneous determination of Atorvastatin calcium and lercanidipine in rat plasma by RP-HPLC and pharmacokinetic studies. Asian Journal of Pharmacodynamics and Pharmacokinetics; 2008; 8; 299-304.
11. Neuvonen PJ, Niemi M, Backman JT.; Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Journal of Clinical Pharmacology and Therapeutics; 2006; 80; 565-581.
12. Sankar P, Subhashree S, Sudharani S.; Effect of Trigonellafoenum-graecum seed powder on the antioxidant levels of high fat diet and low dose Streptozotocin induced type II diabetic rats. Journal of European Review for Medical and Pharmacological Sciences; 2012; 16; 10-17.
13. Scheen A.; Drug–drug and food–drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide; Journal of Clinical Pharmacokinetics; 2007; 46; 93-108.
14. Srinivasan K, Viswanad B, Asrat L, Kaul C, Ramarao P; Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening,; Journal of Pharmacological Research; 2005; 52; 313-320.
15. Takanohashi T.; Inhibition of human liver microsomal CYP by nateglinide. Journal of Pharmceutical research and Pharmacology; 2010; 62; 592-597.
16. Tornio A, Niemi M, Pertti J, Neuvonen TT, Backman G.; Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications; JTPS; 2012; 33; 312-322.
17. Waeber B, Buclin T, Grouzmann E.; Angioedema during ACE and DPP-4 inhibition. Journal of Review Medicine; 2010; 6; 28-31.
18. XiangFei J, DeWei S, Ye C, XinGang L, XiaoMeng W, TianYan Z, Wei L.; A high performance liquid chromatography method for the quantitative determination assay of sitagliptin in rat plasma and its application in pharmacokinetics study. Journal of Chinese Pharmaceutical Sciences; 2011; 20; 63-69.